The present invention relates to new sulfonamide URAT-1 inhibitor compounds of formula (I) or a pharmaceutically acceptable salt thereof:
to compositions containing them, to processes for their preparation and to intermediates used in such processes, and to methods of treatment, wherein R
1
, R
2
, R
3
, R
4
, R
5
and R
6
are as defined in the description.
The present invention relates to new sulfonamide URAT-1 inhibitor compounds of formula (I) or a pharmaceutically acceptable salt thereof:
to compositions containing them, to processes for their preparation and to intermediates used in such processes, and to methods of treatment, wherein R
1
, R
2
, R
3
, R
4
, R
5
and R
6
are as defined in the description.
[EN] SULFONAMIDE DERIVATIVES AS URAT-1 INHIBITORS<br/>[FR] DÉRIVÉS SULFONAMIDES UTILISÉS COMME INHIBITEURS DE L'URAT-1
申请人:PFIZER LTD
公开号:WO2014170792A1
公开(公告)日:2014-10-23
The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to new sulfonamide URAT-1 inhibitors of formula (I): or pharmaceutically acceptable salt thereofs, wherein R1, R2, R3, R4, R5 and R6 are as defined in the description. URAT-1 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly gout.
Preparation of Quinol Imide Acetates. VI. Scope and Limitations